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Abstract
Background: Recent advance of genetic testing has contributed to the diagnosis of hereditary pheochromocytoma
and paraganglioma (PPGL). The clinical characteristics of hereditary PPGL are varying among the types of
mutational genes. It is still difficult to specify the pathognomonic symptoms in the case of rare genetic mutations.
Here, we report the case of synchronous bilateral pheochromocytomas and paraganglioma with novel MYC
associated factor X (MAX) gene mutation.
Case presentation: A 24-year-old female had hyperhidrosis and hypertension. Her urine test showed high
normetanephrine and vanillylmandelic acid. Enhanced computed tomography revealed three enhanced masses in
right adrenal gland, left adrenal gland, and left renal hilus. She was diagnosed with PPGL. Because 123I-
metaiodobenzylguanidine scintigraphy indicated the accumulations in the left adrenal gland mass and the left renal
hilus mass and not in the right adrenal gland mass, we performed laparoscopic left adrenalectomy and extirpation
of the left renal hilus mass to preserve the right adrenocortical function. However, her symptoms recurred shortly
after the operation presumably due to unveiling of the activity of the right pheochromocytoma. Following right
adrenalectomy as the second operation, the catecholamine levels declined to normal range. Her genetic testing
indicated the novel germline mutation in MAX gene (c.70_73 del AAAC/p.Lys24fs*40).
Conclusions: MAX germline mutation is recently identified as a rare cause of hereditary PPGL. The deletion
mutation in MAX gene in this patient has never reported before. In the case of bilateral pheochromocytomas, the
surgical indication should be decided considering each patient’s genetic background. Due to the possibility for
other types of malignant tumors, close follow-up is essential for MAX mutation carriers.
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Background
Pheochromocytoma and paraganglioma (PPGL) are neu-
roendocrine tumors that arise from adrenal or extra-
adrenal chromaffin cells, and they can occur either spor-
adically or hereditary [1]. Diagnosing PPGL as hereditary
or sporadic is mandatory, because fatal illnesses other
than PPGL may occur in some hereditary syndromes.
Although multiple endocrine neoplasia type 2, von
Hippel-Lindau disease, and neurofibromatosis type 1
have been studied well among hereditary PPGLs, recent
advance of genetic analyzing technologies have discov-
ered new causal genes [1]. Currently, about 30% of
PPGLs are considered to be caused by germline muta-
tions [2, 3], and their clinical features, such as
localization, age on onset, and malignant potential are
varying among each patient’s genetic background [1].
However, the characteristics of PPGL with some types of
gene mutations have not been fully elucidated due to
their rarity.
We experienced a case of synchronous bilateral pheo-
chromocytomas and paraganglioma with novel MYC as-
sociated factor X (MAX) gene mutation. There have
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been few reports of PPGL with MAX mutation. We
herein report this case and review the related articles.
Case presentation
A 24-year-old female presented to the regional hospital
with complaints of hyperhidrosis and hypertension. She
did not have specific past histories or family history of
PPGL. Her urine test indicated elevated normetanephr-
ine (NM) and vanillylmandelic acid (VMA) excretion.
Then, she was referred to our hospital.
The patient’s blood pressure was 147/106 mmHg. The
results of her 24-h urine collection test are shown in
Table 1, which indicated excess production of catechol-
amine. Contrast-enhanced computed tomography (CT)
indicated three enhanced masses in the right adrenal
gland (3.5 × 2.2 cm; Fig. 1a), left adrenal gland (2.4 ×
1.9 cm; Fig. 1b), and left renal hilus (2.4 × 1.8 cm; Fig. 1c).
Abdominal magnetic resonance imaging showed that all
three masses were hyperintense in T2 weight image.
123I-metaiodobenzylguanidine (MIBG) scintigraphy indi-
cated the accumulations in the left adrenal gland mass
and the left renal hilus mass (Fig. 1d). The accumulation
was not detected in the right adrenal gland mass. Based
on these results, she was diagnosed as bilateral pheochro-
mocytomas and paraganglioma in the left hilus. Because
the hormonal activity of the right pheochromocytoma was
presumed to be low from the result of MIBG scintigraphy,
we planned left adrenalectomy and extirpation of the left
hilus mass to preserve right adrenocortical function. She
preoperatively took doxazosin up to 8 mg/day for alpha-
blockade.
The patient underwent laparoscopic left adrenalectomy
and extirpation of the left renal hilus mass (operating
time: 4:29, blood loss: 62 g). Multifocal nodules and the
thickened adrenal medulla were observed in the cross-
section of the left adrenal gland, whereas the adrenal cor-
tex was thin (Fig. 2a). The cross-section of the left renal
hilus mass is shown in Fig. 2b. The pathological finding
indicated that they were PPGL without invasion to sur-
rounded tissues or blood vessels (Fig. 3a–d). After the op-
eration, her blood pressure declined to normal range. On
the fourth postoperative day, she complained of hyperhi-
drosis, and her blood pressure was elevated again. After
administration of 4 mg doxazosin, her symptoms amelio-
rated. Her 24-h urine collection test showed that NM and
VMA were still at high levels (Table 1), which suggested
that her right pheochromocytoma actively released
catecholamine. Because she was highly suspected to have
some germline gene mutation associated with PPGL, we
performed genetic testing under her and her family’s con-
sent. Genetic testing regarding hereditary PPGL has been
approved by the institutional review board in our hospital.
PCR-direct sequencing method showed that she had het-
erozygous germline mutation in MAX (c.70_73 del
AAAC/p.Lys24fs*40). Accordingly, due to four-nucleotide
deletion in exon 3, premature termination of translation is
anticipated leaving 62-residue polypeptide, whereas MAX
gene usually codes 160 amino acids.
Four months after the first operation, laparoscopic
right adrenalectomy as the second operation was per-
formed (operating time: 2:26, blood loss: 31 g). The
cross-section of the resected right adrenal gland indi-
cated that the adrenal medulla also thickened and the
cortex was thin (Fig. 2c). The pathological finding
showed pheochromocytoma with capsular and vascular
invasion (Fig. 3e, f ). In her 24-h urine collection test
after the operation, NM and VMA declined to normal
range (Table 1). She has not had any evidences of recur-
rence over a current follow-up period of 2 years. She has
not had the symptom of hyperhidrosis, and her blood
pressure is normal without any antihypertensive drugs.
Discussion
MAX is the most conserved dimerization component of
the MYC-MAX-MXD1 network, and they work as tran-
scription factors that regulate cell proliferation, differen-
tiation, and apoptosis [4]. Whereas heterodimerization
of MAX with MYC acts as transcriptional activators,
heterodimers of MAX with MXD1 repress the MYC-
dependent transcriptional activities by antagonizing
MYC-MAX function [5]. This is why MAX is considered
as a tumor suppressor gene. MAX gene mutations were
identified as one of the causes of hereditary PPGLs by
the next-generation whole exome sequencing in 2011
[6]. Among 1694 PPGL patients without germline muta-
tions in RET,VHL, SDHB, SDHC, SDHD, and TMEM127
genes, 16 heterozygous variants of MAX were identified
in 23 patients. According to the clinical and biochemical
features in 19 PPGL patients with MAX germline muta-
tions, seven (37%) patients had a family history of PPGL,
and age at diagnosis was relatively young (median age
34 years old). Thirteen (68.4%) patients had bilateral
pheochromocytomas or multiple pheochromocytomas in
the same gland. Paraganglioma arose in four (21.0%)
Table 1 Results of catecholamine metabolite ratios in 24-h urine collection tests
Pre-1st operation Post-1st operation Pre-2nd operation Post-2nd operation Normal range (mg/day)
Methanephrine 0.15 0.09 0.08 < 0.01 0.05–0.20
Normetanephrine 4.10 2.90 3.50 0.27 0.10–0.28
Vanillylmandelic acid 27.60 16.50 22.00 3.40 1.4–4.9
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patients. Two (10.5%) patients developed metastatic dis-
ease. PPGLs with MAX mutations were likely to gener-
ate predominantly excess norepinephrine [7]. In another
article, PPGL with MAX mutation was characterized as
a syndrome with high penetrance; the estimated pene-
trance reached to 73% by 40 years of age [8]. In our case,
the patient was young without any family history of
PPGL, and she had bilateral PPGL. As noted in previous
report, her NM level was high, whereas metanephrine
level was within normal range. These features are con-
sistent with those described previously. Although various
mutations have been identified in MAX so far [6, 7], the
mutation of c.70_73 del AAAC/p.Lys24fs*40 has not
been reported before. This mutation had led to a change
in the predicted amino acid sequence; the lysine at
codon 24 in the wild-type MAX protein was changed to
a glycine in the mutant MAX protein, and a stop codon
was located 40 codons downstream from codon 24.
Thus, it is proposed that this newly detected mutation
disrupts the MAX protein. In addition, in silico analysis
using MutationTaster supported the pathogenicity of this
deletion mutation.
Fig. 1 Contrast-enhanced CT showed enhanced masses in the right adrenal gland (a), left adrenal gland (b), and left renal hilus (c). d 123I-MIBG
scintigraphy indicated the accumulations in the left adrenal gland mass and the left renal hilus mass
Fig. 2 a Left adrenal gland resected in the first operation. Multifocal nodules were observed in cross-section (shown by white arrows), and whole
adrenal medulla thickened. b The cross-section of the left renal hilus tumor resected in the first operation. c Right adrenal gland resected in
second operation. The adrenal medulla thickened, and the cortex was thin
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Because aberrant MYC-MAX-MXD1 network is impli-
cated in wide-range malignancies, it is worth to be noted
that germline MAX mutation carriers may have in-
creased susceptibility to develop other malignant tumors
[9]. In the literature, two in 19 PPGL patients with MAX
mutations had cancers, breast cancer, and squamous cell
carcinoma of the tongue [7]. The patients of PPGL with
MAX mutation need a close follow-up for not only
recurrence of PPGL but also emergence of other malig-
nant tumors. Recently, the crosstalk between PIK3CA/
AKT1/mTOR and MYC/MAX/MXD1 pathways has
been proposed [10]. The previous article speculates the
effectiveness of mTOR blocking therapy for patients
with malignant PPGL with MAX mutation [11].
The surgical indication of bilateral pheochromocyto-
mas has remained controversial. In our case, we initially
performed unilateral adrenalectomy to preserve her ad-
renocortical function in hope that unilateral adrenalec-
tomy could ameliorate her symptoms. However, the
symptoms recurred shortly after the operation. This
decision was made based on the apparent unilateral ac-
cumulation in 123I-MIBG scintigraphy which indicated
that the left pheochromocytoma was dominant.
Although bilateral adrenalectomy was ultimately re-
quired to ameliorate her symptoms, we consider that
our strategy, e.g., two-step adrenalectomy, was clinically
acceptable. As a matter of course, a close follow-up after
unilateral adrenal resection is essential.
The total adrenalectomy has been a standard treat-
ment for unilateral or bilateral pheochromocytoma [12].
However, patients are put at risk of adrenocortical fail-
ure and need lifelong corticoid supplementation after
total bilateral adrenalectomy. Recently, cortical sparing
adrenalectomy in patients with RET or VHL mutations
which had low risk of malignant PPGL has been
reported [12, 13]. Accordingly, the recurrence rate after
10 years of follow-up was less than 5%, and a normal
glucocorticoid function was retained in more than 50%
cases [13]. In our case, because the left adrenal gland
had multifocal pheochromocytomas and the medullas of
both glands thickened, cortical sparing, in other words,
partial adrenalectomy, seemed to be contraindicated due
to high likelihood of metachronous occurrence of
pheochromocytomas.
Conclusions
We reported a rare case of PPGL with germline muta-
tion in MAX. The surgical indication of bilateral pheo-
chromocytomas should be decided considering each
patient’s genetic background. A close follow-up for both
recurrent PPGL and other types of malignant tumors is
essential for the patients with MAX mutation.
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Fig. 3 Histopathological results of resected PPGLs (hematoxylin-eosin staining). a, b Left pheochromocytoma resected in the first operation (a
low magnification, b high magnification). c, d Paraganglioma in the left hilus resected in the first operation (c low magnification, d high
magnification). e, f Right pheochromocytoma resected in the second operation (e low magnification, f high magnification)
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